[HTML][HTML] COVID-19 and metabolic disease: mechanisms and clinical management

C Steenblock, PEH Schwarz, B Ludwig… - The lancet Diabetes & …, 2021‏ - thelancet.com
Up to 50% of the people who have died from COVID-19 had metabolic and vascular
disorders. Notably, there are many direct links between COVID-19 and the metabolic and …

COVID-19 and diabetes

AK Singh, K Khunti - Annual review of medicine, 2022‏ - annualreviews.org
The prevalence of diabetes in people with coronavirus disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has varied worldwide …

Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis

NN Nguyen, DS Ho, HS Nguyen, DKN Ho, HY Li… - Metabolism, 2022‏ - Elsevier
Background Diabetes is an independent predictor of poor outcomes in patients with COVID-
19. We compared the effects of the preadmission use of antidiabetic medications on the in …

Metformin: a novel weapon against inflammation

B Bai, H Chen - Frontiers in pharmacology, 2021‏ - frontiersin.org
It has become widely accepted that inflammation is a driving force behind a variety of
chronic diseases, such as cardiovascular disease, diabetes, kidney disease, cancer …

Effects of metformin in heart failure: from pathophysiological rationale to clinical evidence

T Salvatore, R Galiero, A Caturano, E Vetrano… - Biomolecules, 2021‏ - mdpi.com
Type 2 diabetes mellitus (T2DM) is a worldwide major health burden and heart failure (HF)
is the most common cardiovascular (CV) complication in affected patients. Therefore …

COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type ii diabetes mellitus: the anti-inflammatory role of metformin

HM Al-Kuraishy, AI Al-Gareeb, M Alblihed… - Frontiers in …, 2021‏ - frontiersin.org
Background: Coronavirus disease 19 (COVID-19) is regarded as an independent risk factor
for acute ischemic stroke (AIS) due to the induction of endothelial dysfunction, coagulopathy …

Pharmacological treatment of COVID-19: an opinion paper

A García-Lledó, J Gómez-Pavón… - Revista Española …, 2021‏ - pmc.ncbi.nlm.nih.gov
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the
most significant and saving advance against the pandemic. The development of vaccines …

Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews

J Hartmann-Boyce, K Rees, JC Perring… - Diabetes …, 2021‏ - diabetesjournals.org
BACKGROUND This review was commissioned by the World Health Organization and
presents a summary of the latest research evidence on the impact of coronavirus disease …

Mortality risk of antidiabetic agents for type 2 diabetes with COVID-19: a systematic review and meta-analysis

C Kan, Y Zhang, F Han, Q Xu, T Ye, N Hou… - Frontiers in …, 2021‏ - frontiersin.org
Aims We conducted a systematic review and meta-analysis to assess various antidiabetic
agents' association with mortality in patients with type 2 diabetes (T2DM) who have …

Metformin in patients with COVID-19: a systematic review and meta-analysis

Y Li, X Yang, P Yan, T Sun, Z Zeng, S Li - Frontiers in Medicine, 2021‏ - frontiersin.org
Importance/Background: The coronavirus disease (COVID-19) pandemic is a critical public
health issue. Evidence has shown that metformin favorably influences COVID-19 outcomes …